BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Laurus Labs Ltd. Share Price

NSE
BSE

NSE : LAURUSLABS

BSE : 540222

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

₹1,954.00

High

₹1,982.00

Price Summary

Previous Close ₹1,954.00
Day's Range ₹1,954.00 - ₹1,982.00
Open ₹1,962.00
52 Week Range ₹823.10 - ₹1,982.00
Volume 26,55,873
Market Cap ₹0.11
Previous Close ₹1,955.25
Day's Range ₹1,955.25 - ₹1,981.25
Open ₹1,960.00
52 Week Range ₹822.85 - ₹1,981.45
Volume 54,069
Market Cap ₹0.11

Stocks Summary

Trade Value ( ₹ in Lacs) 52,252.95
Market Cap (₹ in Mn) 0.11
Dividend Yield(%) 0.10
Price/Earning (TTM) 96.62
TTM EPS (₹) 20.24
P/E Ratio 60.25
Book Value(₹) 18.73
PAT Margin (%) 13.06
Face Value (₹) 2.00
ROCE(%) 18.20
Trade Value ( ₹ in Lacs) 1,065.35
Market Cap (₹ in Mn) 0.11
Dividend Yield(%) 0.10
Price/Earning (TTM) 96.62
TTM EPS (₹) 20.24
P/E Ratio 60.25
Book Value(₹) 18.73
PAT Margin (%) 13.06
Face Value (₹) 2.00
ROCE(%) 18.20

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 14327.5 55539.6
Expenses N/A N/A
PBT 2114.4 4882.2
Operating profit 0.0 0.0
Net profit 1579.4 3583.4

Shareholding Pattern

Promoters (% Holding)

27.47%

Mutual funds (% Holding)

10.15%

Non-Institution (% Holding)

30.79%

FI/Banks/Insurance (% Holding)

2.33%

Government (% Holding)

0.00%

FII

28.00%

About Laurus Labs Ltd.

Founded 2005
NSE Symbol LAURUSLABS

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,40,397.93 1,835.50 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 2,48,664.42 9,367.00 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,82,738.23 4,804.25 3,480.60 - 3,480.60
Apollo Hospitals Enterprise Ltd. 1,26,102.74 8,770.25 6,696.50 - 6,696.50
Lenskart Solutions Ltd. 1,22,899.37 706.60 0.00 - 0.00
Zydus Lifesciences Ltd. 1,15,012.19 1,153.00 835.50 - 835.50
Cipla Ltd. 1,10,793.75 1,371.45 1,165.70 - 1,165.70
Laurus Labs Ltd. 1,05,644.55 1,955.25 823.10 - 823.10
Max Healthcare Institute Ltd. 1,02,684.23 1,055.00 903.00 - 903.00
Aurobindo Pharma Ltd. 99,828.06 1,735.00 1,066.80 - 1,066.80
no-content No Records Found

Latest News

Aug
31
2026
EQUITY Posted on Aug 31st 2026

Laurus Labs submits analyst meet intimation

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Laurus Labs has informed that the Company will be participating in Investor Conference in group meeting on September 07, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
Sep
19
2026
EQUITY Posted on Sep 19th 2026

Krsnaa Diagnostics informs about updates

Krsnaa Diagnostics has informed regarding the voting results as the outcome of the postal ballot dated September 17, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
Sep
19
2026
EQUITY Posted on Sep 19th 2026

Unichem Laboratories informs about disclosure

Unichem Laboratories has informed that with reference to earlier intimation dated 24th January 2025, the Company has received Order-In-Appeal from Commissioner (Appeals Thane). Relevant details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are provided in Annexure A. The Company shall take all appropriate remedial steps including filing of an appeal within prescribed timelines.
The above information is a part of company’s filings submitted to BSE.
Read More
Sep
19
2026
EQUITY Posted on Sep 19th 2026

HealthCare Global Enterprises informs about scrutinizer’s report and voting results

HealthCare Global Enterprises has informed that 28th Annual General Meeting (AGM) of the Members of the Company was held on Friday, September 18, 2026, at 5.00 PM (IST) through Video Conferencing (‘VC’)/ Other Audio Visual Means (‘OAVM’) in compliance with the General Circulars issued by the Ministry of Corporate Affairs (‘MCA’) and circulars issued by the Securities and Exchange Board of India (‘SEBI’) and as per the applicable provisions of the Companies Act, 2013 and Listing Regulations. All the resolutions set out in the AGM notice have been approved by the Members with requisite majority. In this regard, it has enclosed the following: (i) Consolidated report dated September 18, 2026, of the Scrutinizer signed by Pradeep B Kulkarni, Partner, V. Sreedharan & Associates, Company Secretaries, on e-voting and voting at the Annual General Meeting, in compliance with the provisions of Section 108 of the Companies Act, 2013 and Rule 20(4)(xii) of the Companies (Management and Administration) Rules 2014, annexed as Annexure-A and (ii) Voting results in compliance with Regulation 44(3) of the Listing Regulations read with SEBI Circular, annexed as Annexure- B. The above information is also available on the website of the Company and can be accessed at: https://www.hcgoncology.com/. 
The above information is a part of company’s filings submitted to BSE.
Read More
Sep
19
2026
EQUITY Posted on Sep 19th 2026

Krsnaa Diagnostics informs about voting results of postal ballot and scrutinizer report

With reference to its letter no. KDL/SE/032/2026-27 dated August 18, 2026, Krsnaa Diagnostics has informed that it enclosed the Postal Ballot Notice dated August 13, 2026 (‘Notice’) for seeking approval of the shareholders of the Company on special resolution: Approval for Issuance of up to 16,21,000 Warrants Convertible into Equity Shares of Face Value Rs.5/- each on a Preferential Basis to the Promoter and Promoter Group of the Company.  Pursuant to Sections 108, 110 and other applicable provisions, if any, of the Companies Act, 2013 (‘the Act’) read with the Companies (Management and Administration) Rules, 2014, guidelines prescribed by the Ministry of Corporate Affairs through various Circular(s) and the Listing Regulations, as amended from time to time, the Postal Ballot was conducted through remote e-voting process. The remote e-voting process concluded on Thursday, September 17, 2026, at 17:00 Hrs. (IST), post which Dinesh Shivnarayan Birla (Membership No.: FCS-7658, COP: 13029), Practicing Company Secretary and Proprietor of Dinesh Birla & Associates, Company Secretaries, Scrutinizer submitted the Report on the Postal Ballot voting results on September 18, 2026. Based on the Scrutinizer’s Report, the company has informed that the Special Resolution mentioned in the Postal Ballot Notice dated August 13, 2026 has been passed by the Members of the Company with requisite majority on September 17, 2026, i.e., the last date of remote e-voting. In connection with the above, it has enclosed the following: a. Voting results pursuant to Regulation 44(3) of the Listing Regulations and Section 108 of the Act read with the Companies (Management and Administration) Rules, 2014; and b. Scrutinizer's Report dated September 18, 2026 on remote e-voting.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Laurus Labs Ltd. ?

The current share price of Laurus Labs Ltd. is ₹1,954.00 as of 2026-09-18.

The market capitalisation of Laurus Labs Ltd. is ₹105,644.55 as of 2026-09-18.

The 1-year return of Laurus Labs Ltd. is 1,030.75% as of 2026-09-18.

The P/E ratio of Laurus Labs Ltd. is 60.25 as of 2026-09-19.

The 52-week high and low of Laurus Labs Ltd. are ₹1,982.00 and ₹823.10, respectively, as of 2026-09-18.

The dividend yield of Laurus Labs Ltd. is 0.1023% as of2026-09-18.

You can buy Laurus Labs Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Laurus Labs Ltd. is .

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

People Also Ask

What healthcare products are provided by Laurus Labs Ltd.?

Laurus Labs Ltd. provides active pharmaceutical ingredients, generic formulations and contract‑development/manufacturing services, with strengths in antivirals, oncology and chronic therapies.

Laurus Labs Ltd. collaborates via API and formulation supply agreements and CDMO partnerships with global generic and branded pharma companies that serve hospitals worldwide.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore